These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 35056088)

  • 1. Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.
    Rouhana S; Virsolvy A; Fares N; Richard S; Thireau J
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranolazine and its Antiarrhythmic Actions.
    Polytarchou K; Manolis AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):31-9. PubMed ID: 26245658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
    Antzelevitch C; Belardinelli L; Wu L; Fraser H; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Goodrow RJ; Scornik F; Perez G
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S65-83. PubMed ID: 15378132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
    Shenasa M; Assadi H; Heidary S; Shenasa H
    Card Electrophysiol Clin; 2016 Jun; 8(2):467-79. PubMed ID: 27261835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
    Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
    Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
    Scirica BM; Morrow DA; Hod H; Murphy SA; Belardinelli L; Hedgepeth CM; Molhoek P; Verheugt FW; Gersh BJ; McCabe CH; Braunwald E
    Circulation; 2007 Oct; 116(15):1647-52. PubMed ID: 17804441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiarrhythmic properties of ranolazine: A review of the current evidence.
    Gupta T; Khera S; Kolte D; Aronow WS; Iwai S
    Int J Cardiol; 2015; 187():66-74. PubMed ID: 25828315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.
    Kloner RA; Dow JS; Bhandari A
    Cardiovasc Ther; 2011 Aug; 29(4):e36-41. PubMed ID: 20626400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
    Peters CH; Sokolov S; Rajamani S; Ruben PC
    Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.
    Sokolov S; Peters CH; Rajamani S; Ruben PC
    Front Pharmacol; 2013; 4():78. PubMed ID: 23801963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
    Cingolani E; Lepor NE; Singh BN
    Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging clinical role of ranolazine in the management of angina.
    Vadnais DS; Wenger NK
    Ther Clin Risk Manag; 2010 Oct; 6():517-30. PubMed ID: 21063462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
    Schram G; Zhang L; Derakhchan K; Ehrlich JR; Belardinelli L; Nattel S
    Br J Pharmacol; 2004 Aug; 142(8):1300-8. PubMed ID: 15277312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on ranolazine in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells.
    Chen BS; Lo YC; Peng H; Hsu TI; Wu SN
    J Pharmacol Sci; 2009 Jul; 110(3):295-305. PubMed ID: 19609066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.